Myopic shift during hyperbaric oxygenation attributed to lens index changes. by Evanger, Knut et al.
 Myopic Shift during Hyperbaric Oxygenation Attributed to Lens Index Changes 
 
Knut Evanger, MSc, Barbara K. Pierscionek, PhD, Guro Vaagbø, MD, Einar Thorsen, MD, PhD, 
and Olav H. Haugen, MD, PhD 
 
Institute of Clinical Medicine, University of Bergen, Bergen, Norway (KE, OHH), Faculty of 
Science Engineering and Computing, Kingston University, Kingston-upon-Thames, United 
Kingdom (BKP), Hyperbaric Medicine Unit, Department of Occupational Medicine, Haukeland 
University Hospital, Bergen, Norway (GV, ET), Department of Clinical Science, University of 
Bergen, Bergen, Norway (, ET), and Department of Ophthalmology, Haukeland University 
Hospital, Bergen, Norway (OHH) 
 
Short title: Hyperbaric Oxygenation Myopia Attributed to Lens Index Changes 
 
 
 
3 tables; 2 figures 
 
 
 
Received: ; accepted May 21, 2015. 
  
Final manuscriptKAZMAB
ABSTRACT 
Purpose. To examine ocular lens parameters and structural changes in order to elucidate 
mechanisms underlying the myopic shift and cataract-related changes that occurs in some 
patients during hyperbaric oxygen (HBO) therapy. Methods. Scheimpflug images (Nidek EAS-
1000) of the crystalline lens, measurements of scattered light, objective refraction, keratometry, 
tonometry and axial length of the eye were obtained after the first day of HBO therapy, and 
repeated when patients had completed 19 days of the treatment. Results. Significant reduction in 
mean optical density was found in the lens nucleus, 2.8  4.3 units (p = 0.009) and 2.2  4.1 
units (p = 0.027) within circular and oval areas, respectively. Significant decrease in mean 
backward scattered light was measured, 0.4  0.8 units (p = 0.022). Mean myopic shift was 
0.58  0.39 D (p < 0.001), while cortical optical density, forward scattered light, lenticular 
parameters, keratometry, tonometry, anterior chamber depth and axial length of the eye appeared 
unchanged. Conclusions. Transient myopic shift reported in patients during HBO therapy is 
attributed to changes in the refractive index of the lens. No changes in lens curvatures or 
thickness were found after treatment. 
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The crystalline lens is an avascular transparent organ and under normal physiological conditions 
embedded in a low oxygen environment. During hyperbaric oxygen (HBO) therapy in a 
monoplace chamber, the patient is surrounded by pure oxygen at a pressure higher than 
atmospheric. The monoplace chamber compresses one patient at a time, placed in a supine 
position. Breathing oxygen at high pressure increases the transfer of oxygen from blood to tissue 
in an attempt to revitalize oxygen-dependent metabolism in ischemic body tissue. HBO therapy 
is a commonly used medical treatment in a variety of human diseases, including radiation-
induced osteonecrosis, proctitis and cystitis following previous cancer therapy. 
 
A temporary myopic shift has often been described in patients treated with HBO therapy.1-6 In a 
previous article, we reported that the myopic shift was caused by changes in the crystalline lens 
because the refractive changes appeared only in phakic and not in pseudophakic eyes.5 Changes 
in other optical refractive elements of the eye did not explain the degree of the myopic shift.4-6 
The myopic shift appears to be fully reversible within 10 weeks after completion of the 
treatment.6 
 
To achieve high quality of vision, the crystalline lens must allow for the unimpeded passage of 
light and provide sufficient refractive power to focus a sharp image on the retina. The refractive 
index is determined by the concentration of lens proteins,7 the composition and distribution of 
which influence the amount of light scatter, absorption and transmission through the lens tissue. 
Formation of nuclear cataract has been observed in a patient after a standard course of 
therapeutic HBO,8 and oxidative stress causing damage to lens components is proposed to play 
an important role.9 Development of nuclear cataract is reported after extended periods of HBO 
exposure in patients with initially clear lenses before the start of treatment.10 
 
The visual side effect of HBO therapy is reported to be a cumulative process,5,11 and each daily 
treatment session is of equal oxygen load and duration. Changes in lenticular transparency may 
therefore take place long before any changes of the lens are clinically detectable by slitlamp 
examinations.11 Any explanation of the mechanism causing the refractive changes must also take 
into account that both significant myopic shifts1-6 and hypermetropic shifts12,13 may occur in 
patients treated with HBO therapy. 
 
The present study was undertaken to examine lens surface curvatures, axial thickness and 
structural changes in order to elucidate the mechanisms underlying the myopic shift and cataract-
related changes that occur in some patients during hyperbaric oxygen therapy. Ocular refraction, 
central corneal radius, intraocular pressure, anterior chamber depth and axial length of the eye 
were additionally monitored to verify if these variables were consistent with previously reported 
values. 
 
MATERIALS AND METHODS 
Patients referred to Haukeland University Hospital for elective HBO therapy were invited to take 
part in the study as they presented for the treatment. Twenty patients (10 males and 10 females) 
with a mean age of 56.0  7.7 years, (age range 44 to 68 years) met the inclusion criteria, and 
attended the daily scheduled HBO sessions without interruptions. All had treatment for radiation-
induced osteonecrosis, proctitis or cystitis. All the patients were of Caucasian origin. 
The protocol was approved by the Regional Ethics Committee and the Norwegian Data 
Inspectorate. Eye examinations were performed with the full understanding and written consent 
of each patient, according to the tenets of the Declaration of Helsinki for research involving 
human subjects. Inclusion criteria were age below 70 years, normal ocular health and a spectacle 
prescription within  5.00 D. None of the patients had visual complaints or any subjective 
reduction in visual acuity. Those with HBO therapy during the past 12 months, radiotherapy of 
the orbit, corneal refractive surgery or any wearing of contact lenses were excluded to avoid 
effects on corneal curvature. All measurements were conducted by the same investigator (KE) to 
avoid inter-examiner bias. 
 
HBO therapy was given once daily for 20 days, five days a week in accordance with the standard 
protocol.5 The patients were compressed with oxygen in a monoplace hyperbaric chamber to a 
total pressure of 240 kPa over a period of 10-15 minutes. 100% oxygen was breathed at this 
pressure for 90 minutes, in three cycles of 30 minutes, interrupted by breathing compressed air 
from an oronasal mask for five minutes between the cycles. After each treatment session, the 
patients were decompressed to normal atmospheric pressure in 7-10 minutes. 
 
The eye examination consisted of objective refraction, keratometry, measurements of forward 
scattered light, intraocular pressure, axial length of the eye, Scheimpflug pictures (lens optical 
density, lens surface curvatures, anterior chamber depth, axial lens thickness, pupil diameter), 
and backward scattered light. A routine eye examination with the slitlamp biomicroscopy and 
ophthalmoscopy was also undertaken. Patients arrived to the hospital late in the afternoon the 
day before, or in the morning on the day they started the HBO therapy. There was no time to 
perform the eye examination before the patients entered the chamber on the first day of 
treatment. For this reason baseline measurements were performed in the afternoon after 
completion of the first session of HBO therapy (day 1). Follow-up measurements were repeated 
in identical sequences within the same hour of the day when the patients had completed 19 days 
of the regular treatment. 
 
Objective refraction and keratometry were assessed with the Nidek ARK 900 auto-
refractor/keratometer (Nidek Co., Ltd., Gamagori, Japan). Refractive changes measured with this 
instrument through an undilated pupil have previously shown high correlations both between the 
right and left eye and with subjective refraction5. Hence, in the present study, the subsequent 
measurements and data comparisons were taken from the right eye only. 
 
Forward scattered light was measured with the C-Quant straylight meter (Oculus Optikergeräte, 
Germany), which is based on the compensation comparison method.14-16 The patient focuses with 
one eye on the circular test field, which is divided into a right and a left semicircle. 
Compensating light is randomly presented in one of the two semicircles. A number of short 
stimuli are presented during the test, and the patient activates the corresponding right or left push 
button depending on which of the two semicircles flickers more intensely. A logarithmic 
straylight parameter value (log s, base 10) is established for the C-Quant, and determines the 
ratio between the scattered light and the non-scattered light. With log s notation, the straylight 
value changes linearly. Equal differences in log s correspond to equal differences in s ratio, and 
an increase of 0.3 correlates with a doubling of the amount of straylight. An average logs value 
for young healthy eyes is around 0.9.15 Quality parameter Q  1.0 and Estimated Standard 
Deviation (ESD)  0.08 were used as limits for reliable measurements.14 An ICare Rebound 
tonometer (Tiolat Oy, Helsinki, Finland) was applied to monitor intraocular pressure.17 
 
All the above-mentioned examinations were performed through undilated pupils. Due to 
logistical considerations and in order to reduce patients waiting time, mydriatic eye drops were 
administered before the patients moved to complete the measurements in another laboratory. The 
final examinations included Scheimpflug imaging, which require a wide open pupil. A minimum 
4 mm diameter pupil is required for backward scattered light assessment.18 Axial length of the 
eye was measured before the Scheimpflug imaging as the instrument was located in the same 
room and can be used both with and without pupil dilatation. Table 1 show all measurements 
listed in the order taken. 
 
Axial length of the eye was measured with the IOLMaster (Carl Zeiss Meditec, Jena, Germany) 
and displayed as the distance from the anterior cornea to the vitreo-retinal interface. A Nidek 
Model EAS-1000 anterior segment analysis system (Nidek, Gamagori, Japan) was used to 
measure optical density of the lens, lens surface curvatures, anterior chamber depth and axial 
lens thickness. The system is based on computer analysed photographs captured according to the 
Scheimpflug principle19,20 in combination with slit lamp illumination. Two Scheimpflug pictures 
were taken at the same conditions before and after HBO therapy. A vertical slit beam of 0.08 x14 
mm, with wavelength 880 nm and flash level of 200 Ws was projected into the eye. Backward 
scattered light is produced when the slit beam passes through the lens and is captured by a 
Charged Couple Device (CCD) camera at the temporal side at an angle of 45° to the slit beam 
optical axis.20 From a well-focussed cross-sectional picture of the lens displayed on a LED 
monitor (screen resolution 1920 x 1080), biometrical data of the anterior segment was analyzed 
with the EAS-1000 computer software (version 1.23E). Backward scattered light was analyzed in 
the “Densitometry” program, and measured as optical density. A point just in front of the 
anterior lens capsule (defined as density = 0) was chosen and compared with the density values 
at different locations within the lens. Subsequent points along the central optical axis line within 
the anterior sub-capsular region were measured. Average optical density was measured within 
oval areas (40 x15 pixels) in the anterior and the posterior cortex (Figure 1A). In the lens 
nucleus, average optical density was measured within both circular areas (35 x 35 pixels), and 
oval areas (75 x 35 pixels). The density measurement were graded in 256 (0-255) pixel grayscale 
instrument specific units.21 
 
Lens surface radius was examined in the “Axial Biometry” program by placing the cursor on 
three intersecting points along the curvature of the anterior surface and the posterior surface of 
the lens (Figure 1B). Anterior chamber depth was examined by placing the cursor along the 
optical axis, and displayed as the distance between the intersection points at the posterior cornea 
and anterior apex of the lens (one pixel equals about 0.026 mm).21 Axial thickness of the lens 
was measured along the optical axis (Figure 1C). The pupil diameter was measured as the largest 
vertical edge-to-edge distance, in order to verify size of the pupil during dilatation. 
 
Backscattered light was captured with the Lens Opacity Meter 701 (Interzeag, Schlieren, 
Switzerland). This instrument projects a cylindrical light beam of 1.5 mm in diameter and with 
wavelength 700 nm into the eye directed along the optical axis. A photometer detects changes in 
backscattered light at a fixed angle of 27° below the incident beam. Lens Opacity Meter provides 
a quantitative measure of the degree of opacification in the axial part of the lens on a numerical 
scale in instrument specific units from 0 (clear lens) to 99 (dense cataract).18,22 
 
Both the backscattered light measurements and the Scheimpflug pictures were made 40 minutes 
after administration of cyclopentolate 1% eye drops and in a dark room with only illumination 
from the instrument available. A pupil diameter of 6.00 mm or larger was achieved in all patients 
both at baseline and at the follow-up visits. The posterior section of the lens appeared visible in 
six of the 20 patients on the Scheimpflug pictures. 
 
Lens refractive power was calculated using the Gullstrand-Emsley relaxed eye indices of 
refraction,23 together with the lens curvatures and lens thickness acquired from the Scheimpflug 
images. The lens surface power was obtained from the equation: 
 F = (1.416 – 4/3)/r 
Here F is the power of the lens surface, and r is the absolute value of the radius. These 
parameters were implemented into the customary thick lens formula: 
 LP = F1 + F2 – t/n F1 F2 
in which LP is the equivalent lens power, F1 and F2 are the anterior and posterior lens surface 
powers, t is the lens thickness (in metres), and n is the refractive index of the lens (1.416). 
 
Statistics 
The objective refractive state values were converted into spherical equivalent refraction (sphere 
power + 1/2 of the cylinder power) as provided by the auto-refractor/keratometer and applied in 
the refractive change analysis. A Students paired t-test was used for comparison of ocular 
variables measured at the initial eye examination and the follow-up visit. Mean values are given 
together with standard deviation (mean ± SD), median, minima and maxima. Data analyses were 
conducted using the SPSS for Windows 22.0 program (2013). All probabilities quoted are two-
sided and statistical significance was taken as p < 0.05. 
 
RESULTS 
Refractive Changes 
A significant mean myopic shift occurred for the full sample of 20 patients during treatment, 
0.58  0.39 D (ranged 0.00 D to 1.50 D) (p < 0.001). The refractive changes were mainly 
found in the spherical component. Eighteen of the eyes showed shifts in astigmatism with 
cylinder power  0.25 D, but there were no changes in total cylinder power greater than 0.50 D. 
For the six patients for whom the posterior lens surface data were available (Table 2), a 
significant mean myopic shift of 0.65  0.48 D (ranged 0.00 D to 1.50 D) (p = 0.022) was 
found. The median myopic shift was 0.63 D in both populations.  
 
Forward Scattered Light 
Forward scattered light showed no significant changes from before to after HBO therapy, 0.02 
 0.15 log s units. 
  
Ocular Biometry 
No significant differences in mean central corneal radius (–0.01  0.03 mm), intraocular pressure 
(–0.7  1.8 mmHg), axial length of the eye (0.00  0.02 mm) and anterior chamber depth (0.01  
0.02 mm) were measured. 
 
Lens Optical Density 
There was a decrease in lens optical density after HBO therapy compared to before therapy. The 
nucleus showed a significant reduction in mean optical density after treatment of 2.8  4.3 units 
(range 12.0 units to 4.5 units) (p = 0.009) within the circular areas, and 2.2  4.1 units (range 
10.5 units to 4.5 units) (p = 0.027) within the oval areas (Table 2). Changes in mean optical 
density within the anterior and posterior cortical areas, and peak density in the central sub-
capsular region were not statistically significant. 
 
Lens Curvatures and Thickness 
There were no significant differences in the anterior lens surface radius (–0.01  0.11 mm), 
posterior lens surface radius (0.07  0.13 mm) (n=6) or total axial thickness of the lens (–0.03  
0.04 mm) (n=6) after HBO therapy. The curvatures and thickness measurements from the 
Scheimpflug images were implemented into the customary thick lens formula to estimate the 
lens refractive power before and after treatment. Result of the calculation showed no apparent 
difference in lens refractive power, –0.09 ± 0.16 D (range –0.39 D to 0.03 D) (n=6). There were 
no significant changes in nuclear thickness, anterior cortex thickness or posterior cortex 
thickness following the treatment (Table 3). 
 
Backward Scattered Light 
A small but statistically significant reduction was found in mean backscattered light after HBO 
therapy compared to before the therapy, 0.4  0.8 units (range 2.0 units to 1.0 units) (p = 
0.022). The age-related trends showing an increase with age in backscattered light and nuclear 
optical density at the baseline visit were not changed after the treatment (Figure 2). 
 
DISCUSSION 
A significant myopic shift (–0.50 D) occurred in 13 (65%) single eyes during the study period. 
After three weeks of the treatment, most of the patients noticed a change in visual quality with 
their current correction. The best-corrected visual acuity appears to be stable during a standard 
course of HBO therapy.5,6,12 The myopic shift was not accompanied by any change in 
keratometry or axial length of the eye, indicating that the cause of the myopic shift is related to 
the lens. Lenticular myopia could be caused by steeper lens curvatures, increased axial lens 
thickness, an anterior displacement of the lens, increased refractive index of the lens, or a 
combination of these factors. No changes in surface shape, lens thickness or anterior chamber 
depth were found following treatment. 
 
The significant changes that were found after HBO therapy were a reduction in backward 
scattered light and decrease in nuclear optical density, suggesting that alterations in the media of 
the lens caused the change in refractive status of the eye. Both backscattered light and nuclear 
optical density had natural higher values for older patients before and after HBO therapy. The 
patients participating in this study showed individual changes in myopic shifts ranging from 
0.00D to –1.50 D. Applying the measured lenticular parameters from the Scheimpflug images 
combined with the fixed refractive index from the Gullstrand-Emsley relaxed eye (1.416)23 
revealed no significant differences in calculated lens power after treatment. A change of the 
refractive index value from 1.416 to 1.424 would be sufficient to reach a lenticular power change 
of 1.50 D, which was the maximum shift recorded in this study. Applying a two-index lens 
model (Gullstrand no. 1 parameters)23, 24, there would need to be an increase in the nuclear 
refractive index from 1.406 to 1.412 or a decrease in the cortical refractive index from 1.386 to 
1.337 to produce an increase of about 1.50 D in equivalent power of the eye. 
 
To explain the increase in refractive power as resulting from an increase in nuclear refractive 
index would appear to be inconsistent with the decline in nuclear optical density following 
treatment that was found in this study. The explanation for this apparent contradiction is most 
likely to come from the fact that the lens has a gradient of refractive index in the cortical region 
with a relatively constant refractive index in the nucleus.25,26 Rays of light are refracted when 
they encounter a change in refractive index; the greater the change or the steeper the gradient of 
index, the greater is the refractive power. In a gradient index lens25 structure, a relatively subtle 
change in the shape of the refractive index gradient will alter the equivalent refractive index of 
the lens. If the measured decrease in nuclear optical density does indeed indicate a decrease in 
nuclear refractive index, an explanation for a greater refractive power could be a steepening of 
the gradient index in the cortex25 and would require only subtle changes in local magnitude of 
refractive index. No significant differences were found in the cortical density after treatment, but 
the measure was averaged across a substantial cortical region and hence masked any local 
variations. 
 
The gradient refractive index of the lens is formed by the concentration and distribution of its 
structural proteins: the crystallins, which constitute just over a third of the wet weight of the 
human lens.27 Local changes in refractive index occur when the protein concentration change in 
that region. Since water in the lens exists as either, free water or water bound to proteins, a 
change in local protein concentration can also be related to an increase in the proportion of free 
water as bound water is released.28 The results show a significant decline in lens optical density 
and backscatter, which can be related to a localised change in water state. Since lens proteins are 
not considered to be independent scatterers,29 it may be that the decrease in backscatter is caused 
by a tighter packing of proteins,30-32 which is not incompatible with a release of bound water. 
 
During HBO therapy, the lens equator is exposed to an enhanced concentration of blood-born 
oxygen, which passes the blood-aqueous barrier. HBO exposure to bovine lenses in organ culture 
has been shown to cause reversible optical changes, which progress from the periphery of the 
lens to its centre causing a change in focal length.11 These results support the suggestion that 
HBO treatment causes changes in the cortical gradient. Changes in cortical refractive index 
gradient could also explain the occurrence of hypermetropic shifts that have been reported in 
patients after HBO therapy.12,13 
 
Despite a few exceptional cases that have reported cataract formation in human eyes following 
HBO therapy,8,10 the myopic shifts tend to attenuate and disappear some weeks after completion 
of the treatment.6 Two patients in the study of Palmquist et al. were observed with a partly 
reversible nuclear cataract.10 If indeed variation in the lens refractive index is the cause of the 
myopic shift, the time course of the myopic shift and its reversal need to be taken into account 
when considering the underlying mechanism. 
 
The Lens Opacity Meter measures diffuse changes in backward scattered light from a projected 
cylindrical light beam in the axial part of the lens.18 Adjusted for dilated pupils and age, the 
degree of overall lenticular opacification was within the defined limits of clear lenses18 for all the 
patients during HBO therapy (Figure 2). As the assessment was conducted through a dilated 
pupil with a minimum diameter of 6.00 mm, any absorption by the iris33 would be negligible. 
The minimum pupil diameter appeared slightly larger after the therapy (Table 3). But larger 
pupils would rather release more backscattered light,18 while a reduction in scattered light 
occurred. Backward scattered light from a slit beam (as observed through the biomicroscope 
slitlamp), collect changes from a wider sectional area of the lens and are more susceptible to the 
location and origin of the lens changes.18 No lenses were seen with distinct cortical spoke 
opacities, which could artificially interfere with back projected shadows and thus affect the 
measurements. Hence, the small but significant decrease in backscattered light from the lens 
after HBO therapy could be influenced by reduced fluctuations in the gradient of the refractive 
index25 or by destructive interference.31 
 
Under normal physiological conditions, a myopic shift (1.00 D) occurring over four years in the 
adult human eye might be the first sign of underlying cataract.34 When the lens subsequently 
manifests with increased turbidity and reduced transparency, structural changes may already 
have been underway for some time. Lenticular changes in refraction may take place long before 
any loss of lens transparency can be seen on gross observation in the lens.11 There might 
therefore be an early latency period during HBO therapy, in which scatter is reduced because of 
reorganisation of the crystalline proteins and a change in water content, before this manifests as 
localised aggregations of protein and formation of cataract. Most measuring devices in the 
normal eye care clinic are unlikely to be sufficiently sensitive to detect the variations in 
lenticular optical properties during the very first phase of these changes. 
 
Improved oxygen supply to ocular ischemic tissue may reduce swelling and volume associated 
with low oxygen tension. Resolution of macula oedema and reduced retinal thickness has been 
reported in a diabetic patient during HBO therapy.35 No changes in intraocular pressure or axial 
length of the eye occurred in these patients after treatment, which is in line with results reported 
in other studies using the similar HBO treatment protocol.4,5,12 
 
A limitation of the study is that posterior surface of the lens appeared visible only in one third of 
the patients because of restricted dilation of the pupil. Large pupils are determined by the 
contraction of the dilator pupillae muscles and the relaxation of the sphincter pupillae muscles, 
which are innervated by the sympathetic and parasympathetic nervous system, respectively. 
Hyperbaric oxygen inhalation has shown to increase parasympathetic activity in professional 
divers, and might thus be a contributing factor to the limited mydriasis.36 In addition, senile 
miosis is a well-known phenomenon37 with decrease in pupil area in later adulthood among 
normal subjects. All the patients in this study had reached the age of presbyopia. 
 
In conclusion, the present study shows that the only measurable ocular change accompanying the 
temporary myopic shift in patients undergoing HBO therapy is a significant reduction in 
backscattered light and optical density of the lens. These findings indicate that the myopic shift is 
most likely caused by changes in the structure of the lens tissue, leading to subtle alterations in 
the refractive index gradient. 
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Table 1. Ocular measurements listed in the order taken, the instruments and the units of measurements used. 
 
Variables Mydriasisa Instruments/Analysis Units 
1. Ocular refraction No Nidek ARK 900, Auto-refractor/keratometer Diopters (D) 
2. Corneal curvature radius No Nidek ARK 900, Auto-refractor/keratometer Millimeters (mm) 
3. Forward scattered light No Oculus C-Quant, Straylight meter Logarithmic units (Logs units) 
4. Intraocular pressure No Tiolat ICare, Rebound tonometer Millimeter mercury (mmHg) 
5. Axial length of the eye  Yes Zeiss IOLMaster Millimeters (mm) 
6. Scheimpflug pictures: 
    Lens optical density 
    Lens surface curvatures 
    Anterior chamber depth 
    Axial lens thickness 
    Pupil diameter 
Yes Nidek EAS-1000, Anterior segment analysis Analysis in the 
“Desitometry (Peak)” program 
Analysis of the “Axial Biometry” program Analysis of the “Axial 
Biometry” program 
Analysis of the “Axial Biometry” program 
Analysis of the “Axial Biometry” program 
Arbitrary units (0-255 pixel grayscale units) 
Millimeters (1 pixel = 0.026 mm) 
Millimeters (1 pixel = 0.026 mm) 
Millimeters (1 pixel = 0.026 mm) 
Millimeters (1 pixel = 0.026 mm) 
7. Backward scattered light Yes Interzeag Lens Opacity Meter 701 Arbitrary units (0-99 scale units) 
a Mydriasis was achieved 40 minutes after administration of Cyclopentolate 1% eyedrops  
 
Table 2. Ocular refraction, biometry, light scatter and lens optical density during hyperbaric 
oxygen therapy. 
 
Variables n 
Day 1 after HBO therapy 
Mean ± SD 
Min (Median) Max 
Day 19 after HBO therapy 
Mean ± SD 
Min (Median) Max 
pa 
1. Ocular refraction (D) 20 
0.21 ± 1.46 
–3.88 (0.38) 3.50 
–0.37 ± 1.53 
4.88 (–0.06) 2.88 
< 0.001 
Ocular refraction (D)b 6 
–0.19 ± 0.57 
–1.13 (–0.13) 0.38 
–0.83 ± 0.81 
1.75 (–0.88) 0.38 
0.022 
2. Corneal curvature radius (mm) 20 
7.74 ± 0.33 
7.23 (7.66) 8.24 
7.73 ± 0.33 
7.23 (7.62) 8.24 
0.160 
3. Forward light scatter (logs) 20 
1.16 ± 0.16 
0.84 (1.19) 1.47 
1.15 ± 0.12 
0.93 (1.14) 1.40 
0.653 
4. Intraocular pressure (mmHg) 20 
14.1 ± 3.6 
8.0 (13.7) 23.7 
13.4 ± 3.2 
9.3 (13.0) 23.3 
0.109 
5. Axial length of the eye (mm) 20 
23.36 ± 1.09 
21.44 (23.46) 25.06 
23.36 ± 1.08 
21.43 (23.45) 25.06 
0.427 
6. Scheimpflug pictures:     
Subcapsular density (units), 1 pixelc 20 
74.5 ± 27.5 
22.8 (72.3) 150.5 
73.3 ± 28.4 
24.0 ( 69.0) 142.0 
0.696 
Subcapsular density (units), 2 pixelsc 20 
83.1 ± 30.5 
29.5 (81.8) 162.5 
79.0 ± 28.7 
32.0 ( 67.8) 145.0 
0.257 
Subcapsular density (units), 3 pixelsc 20 
78.1 ± 27.8 
31.0 (79.8) 138.0 
75.6 ± 26.4 
34.0 ( 75.3) 126.0 
0.525 
Anterior cortex density (units)d  20 
56.8 ± 13.9 
38.5 (54.0) 85.5 
55.6 ± 15.5 
29.5 (55.5) 89.5 
0.411 
Nuclear density (units)e 20 
65.1 ± 13.7 
46.0 (63.0) 90.0 
62.3 ± 14.0 
34.5 (61.0) 85.0 
0.009 
Nuclear density (units)f 20 
60.7 ± 12.8 
43.0 (59.8) 83.0 
58.5 ± 13.3 
33.0 (57.3) 79.0 
0.027 
Posterior cortex density (units)g 6 
51.7 ± 3.5 
48.5 (50.8) 57.5 
48.2 ± 5.4 
42.0 (47.0) 56.0 
0.094 
7. Backward light scatter (units) 20 
19.2 ± 3.7 
13.0 (19.3) 27.3 
18.7 ± 3.8 
12.7 (19.0) 28.3 
0.022 
SD, standard deviation; D, diopters; mm, millimeter; Min, minimum; Max, Maximum 
a Paired samples t-test 
b Objective refraction for the six patients of which the posterior lens radius were available 
c Distance from anterior capsular apex (1 pixel = 0.026 mm)  
d Mean optical density within oval areas (40 x 15 pixels) in anterior cortex 
e Mean optical density within circular areas (35 x 35 pixels) in nucleus 
f Mean optical density within oval areas (75 x 35 pixels) in nucleus 
g Mean optical density within oval areas (40 x 15 pixels) in posterior cortex for the six patients the 
posterior lens surface radius were available 
  
Table 3. Lens surface curvatures, axial lens thickness and calculated lens power during 
hyperbaric oxygen therapy. 
 
Variables n 
Day 1 after HBO therapy 
Mean ± SD 
Min (Median) Max 
Day 19 after HBO therapy 
Mean ± SD 
Min (Median) Max 
pa 
6. Scheimpflug pictures:     
Anterior lens surface radius (mm) n=20 
11.09 ± 1.09 
8.75 (11.30) 12.87 
11.08 ± 1.04 
8.79 (11.30) 12.55 
0.617 
Anterior lens surface radius (mm)b n=6 
11.82 ± 0.62 
10.95 (11.81) 12.56 
11.82 ± 0.62 
11.00 (11.82) 12.55 
0.767 
Anterior lens surface power (D) n=6 
6.67 ± 0.35 
6.26 (6.66) 7.18 
6.66 ± 0.34 
6.26 (6.65) 7.15 
0.720 
Posterior lens surface radius (mm) n=6 
7.98 ± 0.24 
7.61 (7.98) 8.31 
8.06 ± 0.33 
7.69 (8.00) 8.64 
0.241 
Posterior lens surface power (D) n=6 
10.35 ± 0.31 
9.94 (10.35) 10.85 
10.27 ± 0.40 
9.56 (10.32) 10.75 
0.225 
Total lens thickness (mm) n=6 
4.22 ± 0.18 
4.03 (4.21) 4.45 
4.18 ± 0.18 
3.91 (4.17) 4.37 
0.179 
Anterior cortex thickness (mm) n=6 
1.13 ± 0.10 
1.02 (1.11) 1.30 
1.13 ± 0.09 
1.06 (1.09) 1.29 
0.662 
Nuclear thickness (mm) n=6 
2.31 ± 0.11 
2.11 (2.32) 2.44 
2.28 ± 0.11 
2.13 (2.29) 2.40 
0.193 
Posterior cortex thickness (mm) n=6 
0.78 ± 0.15 
0.63 (0.72) 0.98 
0.69 ± 0.16 
0.48 (0.67) 0.95 
0.319 
Anterior chamber depth (mm) n=20 
2.88 ± 0.30 
2.23 (2.87) 3.45 
2.89 ± 0.30 
2.27 (2.88) 3.47 
0.089 
Pupil diameter (mm)   n=20 
7.37 ± 0.72 
6.00 (7.38) 8.88 
7.45 ± 0.75 
6.10 (7.42) 8.89 
0.005 
Calculated lens power (D)c n=6 
16.81 ± 0.21 
16.57 (16.85) 17.12 
16.73 ± 0.24 
16.50 (16.69) 17.14 
0.248 
SD, standard deviation; D, diopters; mm, millimeter; Min, minimum; Max, Maximum 
a Paired samples t-test 
b Anterior lens surface radius for the six patients the posterior lens surface radius were available 
c Calculation of lens power uses the lens refractive index (n=1.416)23 from Gullstrand-Emsley relaxed eye 
  
FIGURE LEGENDS 
Figure 1. Scheimpflug images showing (A) optical density within oval areas in the cortex, and 
circular and oval areas in the lens nucleus, (B) anterior lens surface curvature, and (C) 
anterior chamber depth and axial thickness of the lens. 
Figure 2. Backward scattered light (A) and nuclear optical density within oval areas (B) plotted 
against age of the patients. Dark gray dots and dotted regression lines before, and light gray 
dots and solid line after HBO therapy are shown. The arrows show the direction and 
magnitude of the changes. Only light gray dots appear when no changes occur. 
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